Literature DB >> 11982477

Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis.

Marie Chen1, Susan Palleschi, Ali Khoynezhad, Gary Gecelter, Corrado P Marini, H Hank Simms.   

Abstract

HYPOTHESIS: Certain primary breast tumor characteristics can be used to predict positive sentinel lymph node biopsy (SLNB) results and thus determine which patients should undergo SLNB.
DESIGN: Retrospective review of patients undergoing SLNB for invasive breast cancer from March 1, 1998, through March 31, 2001.
SETTING: University-affiliated tertiary care hospital. PATIENTS: Two hundred fifty-seven consecutive patients undergoing successful SLNB. MAIN OUTCOME MEASURES: Correlation of patient age, tumor size, histological subtype, grade, lymphovascular invasion (LVI), host lymphoid reaction, border of neoplasm, characteristics of ductal carcinoma in situ, presence or absence of lobular carcinoma in situ, estrogen receptor, and her-2-neu oncogene status with positive SLNB results. Univariate and multivariate analyses were applied. Stepwise multiple logistic regression analysis identified variables predictive of positive SLNB results (P< or = .05).
RESULTS: : Regression analysis identified tumor size and LVI as the only variables predictive of positive SLNB results. Results of SLNB were positive in 73 (28.4%) of 257 patients (T1a, 5/37 [13.5%]; T1b, 19/93 [20.4%]; T1c, 37/103 [35.9%]; and T2, 12/24 [50.0%]). Although LVI did not correlate with tumor size, it was highly predictive of positive SLNB results by means of the following equation: 1/(1 + e(-z)), where z = 0.3079 + 1.3814 (LVI), -1.1869 (T1a), -0.3235 (T1b), or +0.5724 (T1c).
CONCLUSIONS: Tumor size and LVI were the only variables independently predictive of positive SLNB results. Lymphovascular invasion was the strongest predictor. These data show a higher than expected incidence of positive SLNB for all tumor sizes, which may be explained by results of immunohistochemical analysis of sentinel lymph nodes, and which suggest that all patients with invasive breast cancer should be offered SLNB. Further studies with a larger cohort of patients are warranted.

Entities:  

Mesh:

Year:  2002        PMID: 11982477     DOI: 10.1001/archsurg.137.5.606

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  6 in total

1.  Characterization of circulating tumor cells in newly diagnosed breast cancer.

Authors:  Lu Xu; Songlin Jia; Hengyu Li; Yue Yu; Guoping Liu; Yanmei Wu; Xishui Liu; Chaoqian Liu; Yue Zhou; Zhenzhen Zhang; Yuan Sheng
Journal:  Oncol Lett       Date:  2017-12-06       Impact factor: 2.967

2.  Value of frozen section and primary tumor factors in determining sentinel lymph node spread in early breast carcinoma.

Authors:  Rajshekhar C Jaka; Shabber S Zaveri; S P Somashekhar; R V Parameswaran
Journal:  Indian J Surg Oncol       Date:  2010-08-07

3.  Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla.

Authors:  Sheela Chinnappan; Piyush Chandra; Senthil Kumar; M B Sridev; Deepti Jain; Ganesan Chandran; Satish Nath
Journal:  World J Nucl Med       Date:  2022-06-28

4.  Lymphadenectomy is associated with poor survival in patients with gastrointestinal stromal tumors.

Authors:  Cong Li; Dongfang Su; Chuanbo Xie; Qichen Chen; Jianguo Zhou; Xiaojun Wu
Journal:  Ann Transl Med       Date:  2019-10

5.  Nomograms for Predicting Axillary Lymph Node Status Reconciled With Preoperative Breast Ultrasound Images.

Authors:  Dongmei Liu; Yujia Lan; Lei Zhang; Tong Wu; Hao Cui; Ziyao Li; Ping Sun; Peng Tian; Jiawei Tian; Xia Li
Journal:  Front Oncol       Date:  2021-04-07       Impact factor: 6.244

6.  The appropriate number of ELNs for lymph node negative breast cancer patients underwent MRM: a population-based study.

Authors:  Huiying Chi; Chenyue Zhang; Haiyong Wang; Zhehai Wang
Journal:  Oncotarget       Date:  2017-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.